In somatotroph pituitary tumours, somatostatin analogue (SSA) therapy outcomes vary throughout the studies. We performed an analysis of cohort of patients with acromegaly from the Czech registry to identify new prognostic and predictive factors. Clinical data of patients were collected, and complex immunohistochemical assessment of tumour samples was performed (SSTR1‐5, dopamine D2 receptor, E‐cadherin, AIP). The study included 110 patients. In 31, SSA treatment outcome was evaluated. Sparsely granulated tumours (SGST) differed from the other subtypes in expression of SSTR2A, SSTR3, SSTR5 and E‐cadherin and occurred more often in young. No other clinical differences were observed. Trouillas grading system showed association with age, tumour size and SSTR2A expression. Factors significantly associated with SSA treatment outcome included age, IGF1 levels, tumour size and expression of E‐cadherin and SSTR2A. In the group of SGST, poor SSA response was observed in younger patients with larger tumours, lower levels of SSTR2A and higher Ki67. We observed no relationship with expression of other proteins including AIP. No predictive value of E‐cadherin was observed when tumour subtype was considered. Multiple additional factors apart from SSTR2A expression can predict treatment outcome in patients with acromegaly.

中文翻译：

---

明确定义的肢端肥大症患者队列中肿瘤亚型、SSTR1-5 和 e-钙粘蛋白表达的预测和预后意义

在生长激素垂体肿瘤中，生长抑素类似物 (SSA) 的治疗结果在整个研究中各不相同。我们对捷克登记处的肢端肥大症患者队列进行了分析，以确定新的预后和预测因素。收集患者的临床数据，并对肿瘤样本进行复杂的免疫组织化学评估（SSTR1-5、多巴胺 D2 受体、E-钙粘蛋白、AIP）。该研究包括 110 名患者。在 31 中，评估了 SSA 治疗结果。稀疏肉芽肿 (SGST) 在 SSTR2A、SSTR3、SSTR5 和 E-cadherin 的表达方面与其他亚型不同，并且更常见于年轻人。没有观察到其他临床差异。Trouillas 分级系统显示与年龄、肿瘤大小和 SSTR2A 表达相关。与 SSA 治疗结果显着相关的因素包括年龄、IGF1 水平、肿瘤大小和 E-钙粘蛋白和 SSTR2A 的表达。在 SGST 组中，在肿瘤较大、SSTR2A 水平较低和 Ki67 较高的年轻患者中观察到较差的 SSA 反应。我们观察到与包括 AIP 在内的其他蛋白质的表达没有关系。当考虑肿瘤亚型时，未观察到 E-cadherin 的预测价值. 除了 SSTR2A 表达外，还有多种其他因素可以预测肢端肥大症患者的治疗结果。